CNTX - Context Therapeutics

-

$undefined

N/A

(N/A)

Context Therapeutics NASDAQ:CNTX Context Therapeutics Inc., is a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers. The Company’s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian, and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel, first-in-class small molecule under development as a potent and specific antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Context is headquartered in Philadelphia, PA.

Location: 3675 Market Street, Suite 200, Pennsylvania, 19104, United States | Website: contexttherapeutics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

66.46M

Cash

101.5M

Avg Qtr Burn

-4.601M

Short % of Float

2.62%

Insider Ownership

1.45%

Institutional Own.

76.40%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CT-95 Details
Solid tumor/s

Phase 1

Initiation

CTIM-76 Details
Solid tumor/s, Testicular cancer, Cervical cancer, Ovarian cancer

Phase 1

Initiation

ONA-XR Details
Solid tumor/s, Cancer, Ovarian cancer, Endometrial cancer

Failed

Discontinued

ONA-XR Details
Metastatic breast cancer to brain, ER+/HER2- breast cancer, Breast cancer, Cancer, Solid tumor/s

Failed

Discontinued

ONA-XR Details
Breast cancer, Cancer, Solid tumor/s, Metastatic breast cancer to brain, ER+/HER2- breast cancer

Failed

Discontinued